Home › Hemophilia › Missouri › St. Louis
Hemophilia clinical trials in St. Louis, MO
3 studies for Hemophilia are looking for participants at sites in and around St. Louis (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
RecruitingObservational study
- The John Bouhasin Center for Children with Bleeding Disorders, St Louis
A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)
RecruitingPhase 1Healthy volunteers welcome
- Washington University School of Medicine, St Louis
Efficacy, Safety & Utilisation of Nuwiq, Octanate and Wilate in Previously Untreated & Minimally Treated Haemophilia A Patients
RecruitingObservational study
- St. Louis University , 221 North Grand Boulevard, St Louis
About Hemophilia
Hemophilia is a rare disorder in which the blood does not clot normally. Usually hemophilia usually occurs in males and is inherited. Learn more.
More about Hemophilia on MedlinePlus
Hemophilia trials in other cities
- Indianapolis, IN9 studies
- Los Angeles, CA7 studies
- Seattle, WA6 studies
- Cedar Rapids, IA6 studies
- Philadelphia, PA5 studies
- Little Rock, AR5 studies
- Sacramento, CA4 studies
- Tampa, FL4 studies
- Dallas, TX4 studies
- Atlanta, GA4 studies
- Greenville, NC4 studies
- Orange, CA4 studies
Other studies in St. Louis
- Non-Small Cell Lung Cancer73 studies
- Breast Cancer64 studies
- Metastatic Cancer54 studies
- Colorectal Cancer50 studies
- Cancer (all types)46 studies
- Prostate Cancer46 studies
- Lung Cancer39 studies
- Ovarian Cancer38 studies
- Pancreatic Cancer33 studies
- Endometrial Cancer29 studies
- Head and Neck Squamous Cell Carcinoma28 studies
- Heart Failure26 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.